Deutsche Bank Ag\ Cardiff Oncology, Inc. Transaction History

Deutsche Bank Ag\

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.17 - $2.61 $24,196 - $53,977	-20,681 Reduced 8.45%	224,057 $493,000
Q1 2022 May 13, 2022	SELL	$2.11 - $7.25 $5,186 - $17,820	-2,458 Reduced 0.99%	244,738 $607,000
Q4 2021 Feb 11, 2022	BUY	$5.18 - $7.24 $6,381 - $8,919	1,232 Added 0.5%	247,196 $1.49 Million
Q3 2021 Nov 04, 2021	SELL	$5.01 - $7.58 $379,046 - $573,487	-75,658 Reduced 23.52%	245,964 $1.64 Million
Q2 2021 Aug 11, 2021	BUY	$6.65 - $10.04 $372,586 - $562,521	56,028 Added 21.1%	321,622 $2.14 Million
Q1 2021 May 13, 2021	BUY	$9.1 - $19.57 $2.27 Million - $4.88 Million	249,300 Added 1530.01%	265,594 $2.46 Million
Q4 2020 Feb 16, 2021	BUY	$12.02 - $24.71 $195,853 - $402,624	16,294 New	16,294 $293,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $107M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.